MedPath

Insignis Therapeutics, Inc.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

Not Applicable
Recruiting
Conditions
Type 1 Allergy
Anaphylaxis
Interventions
Drug: Epinephrine Auto-Injector 0.3 mg/0.3 mL
Drug: Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle
Drug: IN-001 9.06 mg Sublingual Spray
Drug: IN-001 13.59 mg Sublingual Spray
First Posted Date
2025-10-07
Last Posted Date
2025-10-07
Lead Sponsor
Insignis Therapeutics, Inc.
Target Recruit Count
30
Registration Number
NCT07210320
Locations
🇺🇸

Washington University in St. Louis School of Medicine, St Louis, Missouri, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.